Peer-Reviewed Articles

Today’s rich oncology pipeline-accounting for nearly 25% of agents in clinical development-promises much needed advances in cancer therapy.

Conducting successful clinical trials in hematological malignancies requires an understanding of a rapidly evolving treatment paradigm that is increasingly nuanced, complex and patient-directed.

An effective risk mitigation model requires the development of a structured approach to risk identification, analysis and control, from trial inception to completion.

It is tempting to imagine the use of the patient's own mobile computing platform for collection of patient-reported outcomes (PROs).

In this article, the authors discuss patient-centered research (also termed "direct-to-patient") that uses the "remote" study approach.

Switzerland is a country small in size, but big in innovation that has always been an attractive location for clinical trials.

The sharp rise in ongoing clinical research studies is driving demand for greater participation in research by physicians as well as by patients.

The organization of healthcare is changing rapidly.

Timely completion of clinical trials is the weak link in the drug development process, and there is no shortage of suggestions for how to improve it.

It is estimated that by the end of 2014, pharmaceutical companies will lose approximately $78 billion USD as a result of medications going off patent.

Pressure to shorten study start-up timelines puts clinical supply management in the crosshairs.

Method designed to reduce the time gap between protocol approval and recruitment is examined.

eGSP-driven approach focuses on overcoming operational challenges through data integration.

Breaking through the confusion around fair market value when applying the concept to study budgets.

In some countries, the participation in clinical trial, is still the only possibility to be treated.

As funding for clinical research trials decreases and sponsors of clinical studies are under increasingly stringent timelines to obtain FDA approval and get new therapies to market, the need increases for well-managed, efficient, and effective clinical trial sites.

How iterative analysis of subject recruitment data can optimize outcomes during ongoing enrollment.

It is estimated that mobile penetration now stands at 96% globally.

New adaptive study designs, new target diseases, and global studies require on-demand packaging and labeling methods in order to keep operating costs under control.

Computer-based modeling and simulation has advanced numerous industries, from aeronautics and engineering to meteorology and finance.

Clinical trial budget development continues to frustrate industry sponsors and investigative sites.

The Internet and various services using it as a platform evolve at such a rapid pace that it is difficult to keep track of everything and to understand its significance to clinical trials.

The last decade has seen the complexity, size, and costs of clinical trials increase, which has made the task of guaranteeing data quality progressively difficult.

Increasing the speed with which promising pharmacological treatments move from pre-clinical research to patient-care utilization has received increasing focus in recent years.

Study startup underperformance and inefficiency has been a problem for executives who manage clinical research trials for decades.

Maintaining health and safety of patients is a primary objective when conducting any form of research.

As the importance of translational research continues to grow, research institutions are exploring other options to remain competitive players in the academic clinical research arena.

Results from a Multicenter Clinical Trial Using a Quality by Design Methodology, Risk-Based Monitoring and Real-Time Direct Data Entry

Industry news focusing on the people and organizations who work in the clinical trials profession.

Improving diversity, education, and advancement in studies: a look at the IDEAS initiative.